A Changing Outlook for Pancreatic Cancer
- The death of beloved Kate and Allie actress Susan Saint James, who died of pancreatic cancer on Oct. 26 at age 80, has renewed attention to a disease long associated with limited treatment options. Ten years after Harry Potter star Alan Rickman’s death from the same disease, advances in treatment are offering patients and families renewed hope.
- The FDA approved daraxonrasib (Rasonque) in August 2026 for adults with metastatic pancreatic cancer who have had previous treatment. In a major trial, it extended median survival to 13.2 months, compared with 6.7 months with standard chemotherapy.
- In an early Memorial Sloan Kettering study, seven of the eight patients who responded to a personalized mRNA vaccine were still alive four to six years after surgery. Larger trials are underway.
- Genetic testing can point some patients to targeted options, and those with a strong family history should ask about genetic counseling and screening.
Beloved figures including Harry Potter star Alan Rickman, Jeopardy! host Alex Trebek, and Dirty Dancing heartthrob Patrick Swayze also died from pancreatic cancer, bringing attention to a disease long associated with limited treatment options.
Read MoreA Targeted Pill Marks a Major Advance
Among the most consequential developments is daraxonrasib, sold as Rasonque, a once-daily pill from Revolution Medicines that targets RAS proteins involved in cancer growth.“This is by far the most effective treatment ever to be developed for pancreatic cancer,” Dr. Peter Hosein, associate director for clinical research at the Pancreatic Cancer Research Institute at Sylvester Comprehensive Cancer Center, University of Miami, tells SurvivorNet.
“It’s a watershed moment,” Dr. Alan Sandler, chief development officer at Revolution Medicines, told SurvivorNet at the ASCO Annual Meeting in June. “This is what happens when an area that’s historically been so hard to treat finally shows real activity.”
Most pancreatic cancers are diagnosed at an advanced stage, when treatment becomes more difficult. Research presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting showed that daraxonrasib nearly doubled median overall survival compared with chemotherapy in previously treated patients with metastatic disease.
“With this new therapy, we now can double the length of their lives,” Dr. Diane Simeone, director of the Moores Cancer Center at UC San Diego Health, tells SurvivorNet. “This is really a first-generation RAS therapeutic, but now we can build upon this — perhaps move this kind of therapy into first line, and probably most importantly, figure out what the best combinations with this therapy are that will provide even more durable responses for patients.”
WATCH: A ‘Major Advance’ For Patients With Pancreatic Cancer
The randomized phase 3 RASolute 302 trial included 500 previously treated patients. Median overall survival was 13.2 months with daraxonrasib, compared with 6.7 months with standard chemotherapy. These results describe outcomes across a study population and cannot predict how long an individual patient will live.
In August 2026, the FDA approved the drug for adults with metastatic pancreatic adenocarcinoma who have received at least one previous systemic treatment or are not candidates for multiagent systemic therapy. Metastatic means the cancer has spread to distant parts of the body.
Targeting these proteins was historically difficult.
“It’s a very smooth protein. It doesn’t have places for drugs to grab onto,” Dr. Nicholas Hornstein, of Northwell’s Lenox Hill Hospital, told SurvivorNet about KRAS, a member of the RAS family.
RAS mutations are found in roughly 30% of all cancers, including many pancreatic, colon and lung cancers, so progress against them could reach far beyond pancreatic cancer. “I think it’s literally opened the floodgates for what can be done with RAS,” Dr. Sandler said.
The treatment still carries risks, including rash, diarrhea, mouth inflammation, nausea and fatigue, and serious complications can occur.
Understanding Pancreatic Cancer’s Tough Reputation
The pancreas, a gland behind the stomach that aids digestion and regulates blood sugar, sits deep in the abdomen, which makes cancer there hard to detect early. Symptoms such as jaundice (yellowing of the skin or eyes), abdominal or back pain, unexplained weight loss and new-onset diabetes often appear only after the disease has spread.
As a result, pancreatic cancer is the third-leading cause of cancer death in the United States, with an overall five-year survival rate of about 13%, according to the American Cancer Society. Those averages reflect older treatments, however, and can’t predict any one person’s outlook.
What Revolution Medicines Just Announced
Building on the RASolute 302 results, Revolution Medicines presented additional analyses on October 23 at the European Society for Medical Oncology Congress. The findings generally favored daraxonrasib across the RAS mutation groups evaluated, different chemotherapy comparisons and previous treatment settings — including patients whose tumors had no identified RAS mutation.
These exploratory analyses came from the existing trial, not a new study. Some groups were small, making the findings less certain, but the results offer further encouragement about the treatment’s potential reach.
A Conversation With Revolution Medicines’ Chief Development Officer
Researchers are also investigating whether targeting RAS earlier could improve outcomes. In October, Revolution Medicines began treating patients in a phase 3 trial evaluating daraxonrasib with investigational zoldonrasib as an initial treatment for metastatic pancreatic cancer with a RAS G12D mutation. The combination remains experimental.
“We anticipate [that] daraxonrasib will move up into earlier lines of therapy and not just daraxonrasib, but RAS inhibitors in general,” Dr. Anna Berkenblit, chief scientific and medical officer at the Pancreatic Cancer Action Network, previously told SurvivorNet.
For patients and families, these studies represent an important next question: Can a treatment that helps after previous therapy offer even greater benefit when used earlier? Ongoing trials will help answer that question.
Personalized Vaccines Show Lasting Promise
Vaccines that teach the immune system to recognize pancreatic cancer are another area of research, an effort gaining momentum after a personalized mRNA vaccine recently reduced the risk of melanoma returning in a large phase 3 trial.
At Memorial Sloan Kettering Cancer Center, an early trial evaluated autogene cevumeran, an experimental mRNA vaccine personalized using genetic information from each patient’s tumor.
Sixteen patients received it after surgery, alongside chemotherapy and an immunotherapy drug. Eight developed the intended immune response. Of those eight, seven were still alive four to six years after surgery, according to findings presented in 2026.
The study was small and cannot prove the vaccine caused the survival difference between immune responders and nonresponders. A larger randomized trial is evaluating the approach.
Other vaccine research offers promise and important lessons. A randomized phase 2 trial of ELI-002 7P, a KRAS-targeted vaccine, did not meet its primary goal of significantly improving disease-free survival. Strong immune responses and additional analyses nevertheless support continued investigation.
Separately, Johns Hopkins researchers reported significant immune responses in 18 of 20 participants receiving an experimental vaccine intended to intercept pancreatic cancer in people at elevated inherited risk. The study has not established that vaccination prevents the disease.
More Personalized Treatment — and Earlier Detection
Genetic testing can identify additional options. Zenocutuzumab, sold as Bizengri, received FDA accelerated approval for previously treated, advanced pancreatic adenocarcinoma with an NRG1 gene fusion. In the supporting trial, 40% of 30 pancreatic cancer patients experienced measurable tumor shrinkage. Confirmatory research is required.
Certain patients with inherited BRCA1 or BRCA2 variants may qualify for maintenance olaparib after initial platinum-based chemotherapy controls their metastatic disease.
Chemotherapy has improved, too. The FDA-approved NALIRIFOX combination extended median survival to 11.1 months, compared with 9.2 months for gemcitabine plus nab-paclitaxel, in its metastatic pancreatic cancer trial.
Specialized surveillance is also finding cancers earlier in people at high inherited or familial risk. Routine screening is not recommended for average-risk adults, but those with a strong family history or relevant mutation can ask about genetic counseling and surveillance.
Pancreatic cancer remains serious. But a growing range of treatments and research opportunities gives families more options to explore — and meaningful reasons to look ahead.
Questions To Ask Your Doctor
- Could a targeted treatment like daraxonrasib help me?
- Is there a clinical trial I should consider?
- Have I had genetic and tumor testing?
- Am I at higher inherited risk, and should my family consider screening?
Learn more about SurvivorNet's rigorous medical review process.
